
Mizuho Medy Co Ltd
TSE:4595

Mizuho Medy Co Ltd
Revenue
Mizuho Medy Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Mizuho Medy Co Ltd
TSE:4595
|
Revenue
ÂĄ11.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
![]() |
Terumo Corp
TSE:4543
|
Revenue
ÂĄ1T
|
CAGR 3-Years
14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
8%
|
|
![]() |
Olympus Corp
TSE:7733
|
Revenue
ÂĄ985.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
3%
|
|
![]() |
Sysmex Corp
TSE:6869
|
Revenue
ÂĄ501.9B
|
CAGR 3-Years
13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
![]() |
Nihon Kohden Corp
TSE:6849
|
Revenue
ÂĄ224.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
3%
|
|
![]() |
JEOL Ltd
TSE:6951
|
Revenue
ÂĄ203.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
Mizuho Medy Co Ltd
Glance View
Mizuho Medy Co., Ltd. engages in the research, development, manufacture and distribution of in-vitro diagnostic products. The company is headquartered in Tosu-Shi, Saga-Ken and currently employs 173 full-time employees. The company went IPO on 2015-12-17. The firm mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.

See Also
What is Mizuho Medy Co Ltd's Revenue?
Revenue
11.4B
JPY
Based on the financial report for Dec 31, 2024, Mizuho Medy Co Ltd's Revenue amounts to 11.4B JPY.
What is Mizuho Medy Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
12%
Over the last year, the Revenue growth was 4%. The average annual Revenue growth rates for Mizuho Medy Co Ltd have been -5% over the past three years , 12% over the past five years .